Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Anthrax Fusion Toxins with Improved Ability to Penetrate Cells

Posted Aug 21 2013 8:00pm

Description of Invention:
Available for licensing are novel conjugated or fusion proteins comprised of anthrax toxin lethal factor cytolethal distending toxin subunit B. Several human tumor cell lines have been found to be highly sensitive to these toxins with LD50 values in the pM range. In vivo studies in mice have revealed that these toxins selectively treat tumors and have very low systemic toxicity.

Applications:
  • Pharmaceutical compositions to selectively treat cancer
  • Applications to treat or prevent growth of undesirable cells


Advantages:
  • Selective with low systemic toxicity
  • Potent (pM LD50 values)


Development Status:
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)


Inventors:
Stephen H Leppla (NIAID)
Christopher H Bachran (NIAID)


Patent Status:
HHS, Reference No. E-120-2013/0
US, Application No. 61/837,428 filed 20 Jun 2013



For Licensing Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 2617

Updated: 08/2013

Post a comment
Write a comment:

Related Searches